TrialCancer2018

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Kiran Naqvi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.